1Sabine Mihm PhD,Heinz Hartmann MD,Afshin Fayyazi MD,Prof. Dr. Giuliano Ramadori MD.Preferential virological response to interferon-α 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a lowγ-GT/ALT ratio[J].Digestive Diseases and Sciences.1996(6)
2Shiffman ML.Management of hepatitis C[].Clin Perspect Gastroenterol.1998
3Pagliaro L,Peri V,Linea C,Cammà C,Giunta M,Magrin S.Natural history of chronic hepatitis C[].Italian Journal of Gastroenterology and Hepatology.1999
4Ben-Ari Z,Tur-Kaspa R.New trends in liver transplantation for viral hepatitis[].The American journal of Gastroenterology.1997
5Hoofnagle JH,Mullen KD,Jones DB,Rustgi V,Di Bisceglie AM,Peters M,Waggoner JG.Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report[].The New England Journal of Medicine.1986
6Lindsay KL.Therapy of hepatitis C: Overview[].Hepatology.1997
7Connor E,Morrison S,Lane J,Oleske J,Sonke RL,Connor J.Safety, Tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection[].Antimicrobial Agents and Chemotherapy.1993
8Roberts RB,Laskin OL,Laurence J,Scavuzzo D,Murray HW,Kim YT,Connor JD.Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome[].Clinical Pharmacology and Therapeutics.1987
9Glue P.The clinical pharmacology of ribavirin[].Seminars in Liver Disease.1999
10Di Bisceglie AM,Coujeevaram HS,Fried MW.Ribavirin as therapy for chronic hepatitis C[].Annals of Internal Medicine.1995
